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Transitional-cell carcinoma of the renal pelvis
or ureter is a relatively rare disease. Several risk
factors are smoking, occupational carcinogens,
analgesic abuse or Balkan nephropathy. The
grade and stage of the disease have the most sig-
nificant impact on the outcome.The treatment of
renal pelvis and ureter tumours is open or laparo-
scopic surgery varying from conservative to more
extensive surgical procedures, i.e. radical
nephroureterectomy including removal of the
contents of Gerota’s fascia with ipsilateral ureter
and a cuff of bladder at its distal extent. Most
available data are from retrospective studies and
surgery is the mainstay of treatment. Chemother-
apy and/or radiation therapy are possible adjuvant
or primary treatment for selected patients; how-
ever, prospective studies are needed to confirm
their use.
Key words: transitional-cell carcinoma; renal
pelvis carcinoma; ureter carcinoma
Summary
Primary transitional-cell carcinoma (TCC) of
the renal pelvis or ureter is a relatively rare dis-
ease. It accounts for less than 1% of genitourinary
neoplasms and 5–7% of all urinary tract tumours
[1]. Its incidence increases with age, the peak di-
agnosis being in the sixth and seventh decades of
life [2]. Male gender is a factor in increased inci-
dence [1, 2]. TCC arises from the lining surface
epithelium [3]. Adverse prognostic factors are
high grade pathology and/or advanced stage.
Most available data are from retrospective studies
and surgery is the mainstay of treatment.
Chemotherapy and/or radiation therapy are pos-
sible adjuvant or primary treatment for selected
patients; however, prospective studies are needed
to confirm their use.
Introduction
Aetiology and pathology
The aetiology of primary TCC of the renal
pelvis or ureter is similar to that reported for
TCC of the bladder [4]. Heavy cigarette smoking
and chronic use of laxatives or non-steroidal anti-
inflammatory drugs such as phenacetin are re-
ported to be closely associated with this cancer [5,
6]. Occupational exposure to organic chemicals
has been associated with a higher risk of develop-
ing upper urinary tract urethelial cancers in work-
ers in the chemical, petrochemical or plastics in-
dustries [6]. The surface epithelium of the urinary
tract exposed to potential carcinogens may de-
velop a “field cancerisation” resulting in synchro-
nous or metachronous involvement of multifocal
areas [7]. Endemic nephropathies, such as Balkan
nephropathy, an indolent inflammatory process
occurring in the Balkan countries, or nephropathy
from China secondary to the ingestion of Chinese
herbs containing Aristolochia fangchi, used for
weight reduction, are associated with the develop-
ment of TCC of the renal pelvis or ureter [8, 9].
Environmental factors such as radon inhalation or
minerals in drinking water are reported to in-
crease the risk of TCC of the renal pelvis or ureter
[6]. Genetic factors such as Lynch syndrome are
also reported to increase the risk of upper urinary
tract cancers [10, 11].
The most common type of renal pelvis and
ureter cancers is TCC [7, 12]. Squamous-cell car-
cinoma, adenocarcinoma or sarcoma are uncom-
mon [13]. Morphologically, TCC of the renal
pelvis and ureter, like bladder TCC, can be papil-
lary or solid and associated with carcinoma in situ.
The prognosis of TCC is better than in other his-
tological subtypes [14].
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Macroscopic or microscopic haematuria is
present in 75–90% of patients. Flank pain, occur-
ring in 20–40% of patients secondary to an ob-
structive tumour mass, may mimic a ureteral cal-
culus [15]. Urinary symptoms (dysuria, pollaki-
uria, etc) may occur in 25–50% of patients [14,
15]. Physical examination is generally normal,
with the exception of a palpable flank mass in
fewer than 10% of patients.
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Clinical presentation
Staging and diagnostic workup
TCC of the renal pelvis or ureter may spread
locally by direct extension to adjacent anatomical
structures, or may be disseminated by lymphatic
or haematogenous pathways [16]. The primary
tumour is detected by urinary cytology, intra-
venous pyelography and/or ureteroscopy. Routine
staging includes chest radiograph and/or thoraco-
abdominal CT combined with assessment of he-
patic, renal and haematological chemistry. To de-
termine the staging procedure it is essential to as-
certain the distribution of simultaneous tumours
of the urinary tract. Multifocal tumours are fre-
quent, and may arise in the ureter, bladder, or on
the contralateral side. Radionuclide bone scan is
also recommended to exclude bone metastases in
locally advanced disease. The UICC (Union In-
ternationale Contre le Cancer) staging system
classifies this disease according to tumour (T),
nodes (N), and metastases (M) (table 1) [17].
Primary tumour (T)
TX Primary tumour cannot be assessed
T0 No evidence of primary tumour
Ta Papillary noninvasive carcinoma
Tis Carcinoma in situ
T1 Tumour invades subepithelial connective tissue
T2 Tumour invades the muscularis
T3 For renal pelvis only: tumour invades beyond muscularis
into peripelvic fat or the renal parenchyma
For ureter only: tumour invades beyond muscularis into
periureteric fat
T4 Tumour invades adjacent organs, or through the kidney
into the perinephric fat
Regional lymph nodes (N)*
NX Regional lymph nodes cannot be assessed
NO No regional lymph node metastasis
N1 Metastasis in a single lymph node, 2 cm or less in greatest
dimension
N2 Metastasis in a single lymph node, more than 2 cm but
not more than 5 cm in greatest dimension; or multiple
lymph nodes, none more than 5 cm in greatest
dimension
N3 Metastasis in a lymph node more than 5 cm in greatest
dimension
Distant metastasis (M)
MX Distant metastasis cannot be assessed
MO No distant metastasis
MI Distant metastasis
* Note: laterality does not affect the N classification.
Table 1
Definition ofTNM
staging for tumours
of renal pelvis and
ureter [16].
Treatment of non-metastatic disease
The treatment of renal pelvis and ureter tu-
mours is open or endoscopic/laparoscopic surgery
[18] varying from conservative to more extensive
surgical procedures, i.e. radical nephroureterec-
tomy including the removal of the contents of
Gerota’s fascia with ipsilateral ureter and a cuff of
bladder at its distal extent [19]. Nephron sparing
approaches in well-selected patients with low-
stage and low-grade disease can be treated endo-
scopically by ureteroscopy and percutaneous renal
surgery [18]. Lymphadenectomy should be con-
sidered in locally advanced non-metastatic disease
but its therapeutic effect on the outcome needs
further prospective investigation [20]. The entire
ipsilateral ureter should be removed as 20–50% of
patients with residual ureteral stumps develop tu-
mours within the stump [21, 22]. Following sur-
gery, locoregional failure is reported in 9–15% of
patients with low grade and low stage disease, and
in 30–50% of those with high grade and advanced
disease [23, 24].
In bladder cancer an organ-preserving ap-
proach using combined chemo- and radiotherapy
has proved successful [25–28].The same approach
can also be applied in upper urinary tract tumours
if surgery is not possible.
Despite aggressive primary surgery, locore-
gional failure remains frequent. Adjuvant radia-
tion therapy has been advocated by some authors
[15, 29–33] but its benefit is unclear. Some studies
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suggest no benefit from adjuvant radiotherapy,
but data from clinical experience are limited with-
out conclusive results from prospective studies
[29, 33]. Data from the literature are summarised
in table 2. Generally speaking, in patients with ad-
verse factors such as a high grade or advanced
stage, close or positive surgical margins or posi-
tive lymph nodes, postoperative radiotherapy may
be considered. The role of adjuvant chemother-
apy is also unproven. Recent retrospective results
show that modern cytotoxic agents, combined
with radiotherapy or alone, appear to be associ-
ated with a better outcome [34–37]. In this set-
ting, prospective studies are warranted in large
collaborative groups.
According to data from the National Cancer
Institute SEER programme [3], 5-year overall
survival in TCC of the upper urinary tract is 95%
for in situ tumors, 89% in localized disease, 63%
in node positive patients and 17% in metastatic
disease.
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Author [ref] n Dose (Gy) Residual tumour Results
after surgery
Babaian [30] 8 18.25–59 8 out of 8 Control: 4 of 8; local control: 7 of 8
Brookland [29] 9 40–60 4 of 9 Control: 5 of 9; local control: 8 of 9
11 – 1 of 11 Control: 3 of 11; local control: 8 of 11
Brady [31] 2 40–50 2 of 2 Control: 1 of 2
Cozad [21] 10 37.4–56 3 of 10 Local control: 9 of 10
Czito [37] 31 46.9 5 of 31 Control: 15 of 31; local control: 24 of 31
Maulard-Durdux [32] 26 45 ? Local control: 21 of 26
Ozsahin [22] 45 20–66 15 of 45 Local control: 33 of 45
81 – 18 of 81 Local control: 51 of 81
Zhang [33] 17 42 (IORT) 5 of 17 Local control: 12 of 17
IORT: Intraoperative radiotherapy
Table 2
Postoperative radio-
therapy in urothelial
renal pelvis and/or
ureter tumours: data
from the literature.
Treatment of advanced disease
Many treatment options exist for the manage-
ment of advanced or metastatic disease, including
surgery, radiation therapy and/or chemotherapy,
depending on the patient’s performance status and
comorbidities. Urothelial cancers are reported to
be responsive (39–65%) to cisplatin-based
chemotherapy regimens [38, 39]. Taxanes and/or
gemcitabine have also been used in this setting
[40, 41].
Conclusion
In patients with TCC of the renal pelvis
and/or ureter, radical surgery should be carried
out whenever possible. Locoregional failure rate
remains high. With the introduction of more so-
phisticated treatment planning, conformal tech-
niques and intensity modulation, the role of post-
operative radiation therapy remains to be re-
assessed. Adjuvant chemotherapy using novel
drugs and/or targeted agents should also be evalu-
ated prospectively.
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